ImmuPharma (LON:IMM) Stock Price Down 21.1% - Should You Sell?

Key Points

• ImmuPharma shares dropped 21.1% during mid-day trading, reaching a low of GBX 10.80 ($0.15), significantly increasing trading volume to 45,915,910 shares.
• The company reported negative earnings per share of GBX (0.38) for the last quarter, with analysts forecasting a dramatic decline to -339.00 earnings per share for the current fiscal year.
• ImmuPharma focuses on peptide-based therapeutics, specifically for autoimmune diseases, with its lead program, Lupuzor™, targeting Lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded down 21.1% during mid-day trading on Wednesday . The company traded as low as GBX 10.80 ($0.15) and last traded at GBX 11.76 ($0.16). 45,915,910 shares were traded during mid-day trading, an increase of 438% from the average session volume of 8,530,393 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Stock Performance

The stock's fifty day moving average price is GBX 3.87 and its 200-day moving average price is GBX 3.15. The firm has a market cap of £58.76 million, a PE ratio of -1,321.12 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.